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Objective. The aim of this study was to investigate the local and systemic expression of CC-chemokine ligand 3 (CCL3) and
its receptors (CCR1 and CCR5) in tissue samples and peripheral blood mononuclear cells of recurrent aphthous stomatitis
(RAS) patients.
Study Design. This case-control study enrolled 29 patients presenting severe RAS manifestations and 20 non-RAS patients
proportionally matched by sex and age. Total RNA was extracted from biopsy specimens and peripheral blood mononuclear
cells for quatitative reverse-transcription polymerase chain reaction. The data obtained by relative quantification were
evaluated by the 2Ct method, normalized by the expression of an endogenous control, and analyzed by Student t test.
Results. The results demonstrated overexpression in RAS tissue samples of all of the chemokines evaluated compared with
healthy oral mucosa, whereas the blood samples showed only CCR1 overexpression in RAS patients.
Conclusions. These findings suggest that the increased expression of CCL3, CCR1, and CCR5 may influence the immune
response in RAS by TH1 cytokine polarization. (Oral Surg Oral Med Oral Pathol Oral Radiol 2012;114:93-98)Recurrent aphthous stomatitis (RAS) is the most com-
mon human oral ulcerative disease, showing a world-
wide distribution of 25% of the general population.
The classical presentation of RAS corresponds to mul-
tiple recurring self-limited ulcers mainly involving
nonkeratinized oral mucosa. Most RAS patients present
mild conditions; however, nearly 20% suffer severe
RAS manifestation that greatly compromises quality of
life.1,2
Positive family history in a significant proportion of
RAS patients and identification of specific interleukin
(IL) (IL-1 and IL-6) and tumor necrosis factor (TNF)
 polymorphisms3-5 demonstrate that genetic factors
may play an important role in RAS development.1,6
In addition, there are many local and systemic pre-
disposing factors associated with RAS disease suscep-
tibility, such as local trauma,7 nutritional and hematinic
deficiency,8 food hypersensitivity, breastfeeding his-
tory,6 smoking cessation,9 and psychologic stress.10
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http://dx.doi.org/10.1016/j.oooo.2012.02.031RAS, apparently, does not have an infectious ori-
gin,11,12 but heat shock proteins, such as HSP60, which
have homology between microbial HSPs, may act as a
local antigen increasing the inflammatory reaction.13
All these factors may change the epithelial permeability
or oral tolerance to common antigens, facilitating or
enabling contact with antigenic substances from the
oral cavity that could trigger a proinflammatory im-
mune response.14
These derangements lead to TH1-polarization of the
immune response with elevated local release of proin-
flammatory cytokines, such as IL-2, IL-8, IL-12,
TNF-, and interferon (INF) , and lower production of
antiinflammatory cytokines IL-4, IL-10, and tumor
growth factor (TGF) .15-21 The analysis of Toll-like
receptor (TLR) mRNA expression levels in oral lesion
showed significant overexpression of the TLR2 gene,
which modulates response toward antiinflammatory ef-
fects.22 However, RAS patients present an anomalous
activity of the TLR2 pathway that probably influences
the stimulation of an abnormal TH1 immune response23
and modulates chemokines receptors, in particular
CCR1 and CCR5, influencing monocyte migration after
pathogen recognition by the TLR.24
Statement of Clinical Relevance
This study explores the etiopathogenesis of RAS.
The results indicate that chemokine ligand and re-
ceptors may represent important targets for RAS
therapy and that new functional tests could evaluate
their relationship in this disease.93
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cytokines released by a wide variety of cells and exert
their biologic activities by binding to specific chemo-
kine receptors belonging to the G protein–coupled re-
ceptor superfamily on the target cell plasma membrane.
They potently mediate inflammation by the recruitment
and activation of specific leukocyte subpopulations,
such as macrophages, T and B lymphocytes, eosino-
phils, basophils, and neutrophils.25 Overexpression of
chemokines could be responsible for TH1 lymphocyte
recruitment and activation of the inflammatory re-
sponse against oral tissues, as observed in RAS lesions.
Expression of chemokines has been studied in other
similar chronic inflammatory diseases that present aph-
thous-like ulcers as oral manifestation. Oral and genital
lesions of patients with Behçet disease (BD) revealed
increased expression of IL-8 and monocyte chemoat-
tractant protein (MCP) 1.26 MCP-1 was also systemi-
cally increased even in the inactive stage of BD.27 High
levels of macrophage inflammatory protein (MIP) 1
(CC-chemokine ligand 3 [CCL3]) were found in BD
patients’ serum in both the inactive and the active
stages of the disease.28
The overexpression of specific chemokine genes
(MIP-1/CCL3, MIP-1, MCP-1), detected with mi-
croarray analysis,16 strongly suggests that chemokines
are altered in RAS patients and also demonstrates a
profile of more intense activity of the TH1 gene cluster.
The biologic effects of CCL3 mediated through CC-
chemokine receptor 1 and 5 (CCR1 and CCR5) signal-
ing may contribute to tissue damage and inflammation
by enhancement of T-cell activation, TH1/TH2 cytokine
polarization, stimulation of macrophage function, and
protease secretion. Such prominent expression is of key
importance in the development and progression of au-
toimmune diseases.25 Moreover, these receptors also
seem to play an important role in inflammatory condi-
tions.29
Although chemokines are listed as important factors
in the process of migration and activation of leukocytes
in various inflammatory diseases, little is known about
their expression and role in RAS manifestation. The
present study investigated the local and systemic ex-
pression of CCL3 (MIP-1) and its receptors CCR1
and CCR5 in tissue samples and peripheral blood
mononuclear cells of RAS patients compared with
those of a healthy control group.
MATERIALS AND METHODS
Participants and samples
This study was approved by the local Research Ethics
Committee of the University of São Paulo School of
Dentistry. All patients and volunteers enrolled in the
trial agreed with the terms of a written informed con-sent. Patients and controls were recruited consecutively
from among those who sought treatment at the Stoma-
tology Clinic of the University of São Paulo School of
Dentistry, in accordance with the inclusion and exclu-
sion criteria adopted in the trial.
The study population consisted of 29 RAS patients
(14 men, 15 women, age range 18-64 years, mean age
37.42  14.25 years), presenting severe manifestation of
the disease (at least one episode per month and suffering
from RAS for a minimum period of two years). Patients
were instructed to avoid the use of any topical or systemic
medication for RAS treatment in the two weeks preceding
sample collection. A control group composed of 20 non-
RAS patients proportionally matched by sex and age were
also enrolled in this study (9 men, 11 women, age range
18-58 years, mean age 35.95  12.68 years). The partic-
ipants included in this group were healthy volunteers
without any oral mucosal disease, inflammatory disorders,
with no RAS family history, submitted to third molar
extraction or oral cyst removal, who agreed to donate a
sample of clinically healthy oral mucosa obtained during
soft tissue plasty. Hematologic status was evaluated in all
patients by means of a full blood count, including ferritin,
folate, and vitamin B12 serum levels. Patients with defi-
ciency in any of these parameters were not included in the
study. In both groups, the criteria for patient exclusion
were the presence of diseases or conditions including
anemia, cyclic neutropenia, inflammatory bowel disease,
Behçet disease, HIV infection, cancer or receiving any
cancer treatment, pregnancy, and smoking habit, those
who had taken any systemic or topical medication for
RAS treatment in the previous 15-day period, or those
who were receiving any systemic therapy for other con-
ditions with nonsteroidal antiinflammatory drugs, immu-
nosupressors, antibiotics, antidepressants, ansiolitics, or
nicorandil.
Tissue samples were obtained after administration of
local anesthesia by means of a 5-mm punch biopsy
from an acute (within 72 hours of its onset) aphthous
lesion in the RAS group or from clinically healthy
nonkeratinized oral mucosa (area with no relation to
tooth surface and with no signs of inflammation or
pericoronitis) in the control group. All specimens were
snap-frozen in liquid nitrogen and stored at 80°C up
to the time of the RNA extraction procedure. During
the same clinical appointment for the biopsy procedure,
all patients were submitted to blood sample collection
(10 mL) into EDTA-containing tubes (Becton, Dickin-
son and Co., Franklin Lakes, NJ, USA). All procedures
were carried out during the morning period between 8
and 10 a.m. Blood samples were immediately submit-
ted to the Ficoll-Paque Premium (GE Healthcare, Chal-
font St. Giles, Bucks., UK) protocol for isolation of
peripheral blood mononuclear cells (PBMCs) accord-
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cells were stored at 80°C until further processing.
Quantification of mRNA expression of CCL3,
CCR1, and CCR5 in tissue and blood samples
Total RNA was extracted from homogenized biopsy
specimens and isolated PBMCs with the use of Trizol
reagent (Invitrogen, Carlsbad, CA, USA) in accordance
with the manufacturer’s instructions. Total RNA was
treated with DNase I (Invitrogen) to eliminate genomic
DNA contamination, at room temperature for 15 min-
utes, followed by 10 minutes at 65°C, with addition of
25 mmol/L EDTA to inactivate the enzyme. The RNA
integrity of samples was evaluated based on the inten-
sity of 28S and 18S rRNA bands in 1% agarose gels
and A260/A280 ratio from 1.8 to 2.0, as assessed by
NanoDrop 2000 spectrophotometer (Thermo Scientific,
Wilmington, DE, USA). Total RNA (1 g) was reverse
transcribed with 200 U SuperScript III Reverse Tran-
scriptase (Invitrogen) for 60 minutes at 50°C with the
use of Oligo-dT (Invitrogen) bringing the final volume
to 20 L.
Quantitative real-time reverse-transcription polymer-
ase chain reaction (qRT-PCR) was carried out with the
ABI 7500 Sequence Detection System real-time PCR
machine (Applied Biosystems, Carlsbad, CA, USA)
using Sybr green fluorescence. Gene-specific primer
sets (Table I) were designed for quantitative assays
with the use of the Gene Tool 2.0 software (Biotools,
Edmonton, Alberta, Canada). All PCR reactions were
performed in triplicate in a total volume of 20 L,
containing 8 L diluted cDNA sample (1:10), 1 L of
the set of primers (250 nmol/L) and Sybr Green qPCR
MasterMix (Applied Biosystems). Thermal cycling was
performed at 95°C for 10 minutes’ hold, followed by 40
amplification cycles of denaturation at 95°C for 10
seconds and annealing/extension at 60°C for 1 minutes.
Dissociation curve analysis was performed at the end of
the 40 cycles to verify the identity of the PCR product.
Data were normalized by the expression of an endog-
enous control (GAPDH), and the relative quantification
was evaluated by the 2Ct method, measuring the
Table I. Primer sequences and reaction properties
Target Accession no. (Genbank) Sense and antis
CCL3 NM_002983.1 GCCCGGTGTCA
CCAGTCCATAG
CCR1 NM_001295.2 AGAGGACTATG
ATTGCACAAGG
CCR5 NM_00579.1 TCTCCCAGGAA
ACCGAAGCAGA
GAPDH NM_002046 GCATCCTGGGC
CCACCACCCTGPCR product in the logarithmic phase of the reaction bydetermining the threshold cycle (Ct). A pool of control
samples was used as calibrator.
Statistical analysis
The differential expression levels of the studied genes
among RAS and control blood and biopsy samples
were analyzed by Mann-Whitney test, a nonparametric
test for independent samples, and the results were con-
sidered to be statistically significantly at P 	 .05.
RESULTS
In this study, 29 RAS patients presenting severe man-
ifestation of the disease and 20 non-RAS patients ex-
hibiting hematologic status within normal limits as
checked by full blood count along with ferritin, folate,
and vitamin B12 serum levels were enrolled. Other
clinical characteristics of RAS patients’ disease are
summarized in Table II; the clinical aspects of minor
and major RAS as well as the areas where biopsies
were taken are illustrated in Figures 1 and 2.
Blood samples were collected from all subjects in-
cluded in this trial: 29 from RAS patients and 20 from
healthy volunteers (control group). Biopsy specimens
were obtained according to the eligibility criteria from
15 RAS patients (agreeing to undergo the surgical
procedure, by signing the terms of the informed con-
sent, ulcers within 72 h of onset) and 7 control patients
(agreeing to the donation of the tissue removed during
a surgical procedure by signing the terms of the in-
formed consent, and absence of signs of inflammation).
There was no statistical difference in sex and age
distribution between RAS and control groups (propor-
tionally matched 2:1). Regarding the blood and tissue
substrates, all samples were analyzed for selected gene
expression by qRT-PCR.
The qRT-PCR analysis of mRNA expression lev-
els in oral tissue (biopsy samples) showed significant
overexpression (P 	 .01) of CCR1, CCR5, and
CCL3 in RAS lesions compared with healthy oral
mucosa (Figure 3). Blood samples showed a statis-
tically significant difference only of CCR1 gene ex-
pression (P 	 .05); which was higher in RAS than in
quences Position
Melting
temperature
Product
size
CTAAC 279-299 64°C 217 bp
GGTAGC 475-495
GACCAC 92-112 63°C 164 bp
GGACCA 235-255
CTTTAC 545-565 58°C 191 bp
TTAGGA 715-735
CTGA 917-936 61°C 162 bp
GTA 1,059-1,078ense se
TCTTC
AAGA
ACAC
ACCA
TCAT
GTTT
TACAcontrol samples (Figure 4).
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RAS is the most common human oral ulcerative disease,
with a worldwide distribution.1 The small sample size and
the case-control design of this study did not allow a proper
epidemiologic observation; however, in the population
consecutively included in this trial there was no predilec-
tion for race, sex, or socioeconomic status. Nevertheless,
a large cohort study found more male individuals diag-
nosed with RAS (51%) than female patients (36%), and
those male patients were younger, unmarried, and usually
reported a family history of RAS.6
The most frequently observed RAS was the minor
type (83%), followed by the major type (17%)—her-
petiform type was not observed—in agreement with
published data.1 Reports of family history were fre-
quent in this population (62%), as observed in the
Table II. General characteristics of recurrent aphthous
stomatitis (RAS) group
Characteristic RAS patients, n (%)
Positive family history 18 (62)
RAS classification
Minor 24 (83)
Major 5 (17)
Herpetiform 0 (0)
Related factors
Stress 15 (52)
Food 22 (76)
Trauma 16 (55)
Menstrual cycle 7 (24)
Toothpaste 3 (10)
Fig. 1. Typical minor RAS lesion located at lower labial
mucosa from a 22-year-old female patient, characterized by a
round ulcer with a grayish pseudomembrane and an erythem-
atous halo. The black circle indicates where the biopsy (5-mm
punch) was taken.literature,6,8 supporting a genetic involvement in theetiology of RAS. The trigger factors most frequently
mentioned by patients in the trial were stress (52%),
food (76%), and trauma (55%), as observed in other
studies.10,30 These modifying factors have been exten-
sively studied but do not seem to play a central role in
RAS pathogenesis, which is mainly attributed to im-
munologic and inflammatory disorders.
The high level of expression of certain chemokines in
RAS patients suggests that they may play a part in RAS
pathogenesis.16,19 Assuming that local and systemic pro-
duction of chemokines as well as the presence of chemo-
kine receptors may be determined by quantification of
mRNA, the present study quantified CCR1, CCR5, and
Fig. 2. Multiple major RAS lesions at lower labial mucosa
from a 19-year-old patient characterized by a larger and
deeper ulcer than those found with minor-type RAS. The
black circle indicates where the biopsy (5-mm punch) was
harvested from.
Fig. 3. Chemokine gene expression in tissue samples from 15
RAS patients and 7 control individuals. The bars represent the
log2 mean fold difference  SEM between the 2 groups
quantified with specific primer sets and normalized against
GAPDH mRNA levels.CCL3 mRNA expression levels by means of qRT-PCR in
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RAS patients and healthy volunteers. Biopsy samples
were collected from individuals who agreed to this pro-
cedure by signing an informed consent. The other patients
were submitted only to blood sample collection during an
acute active RAS lesion. This difference did not influence
the statistical analysis.
The results showed overexpression of all chemokines
evaluated in RAS tissue samples compared with
healthy oral mucosa, whereas the blood samples
showed only CCR1 overexpression in RAS patients.
Immunohistochemical analysis has demonstrated that
RAS patients show higher local expression of CCL3
and CCR5 than the control group,19 in agreement with
the results obtained in this study.
Local overexpression of chemokine and chemokine
receptors may reflect the intense inflammatory infiltrate of
both mononuclear and polymorphonuclear cells into the
site of an inflammatory lesion. The local overexpression
of CCL3, CCR1, and CCR5 observed in the present study
was related to severe cases of RAS, characterized by high
frequency of lesions and in some cases major-type lesions,
which present a prominent inflammatory infiltrate.
CCR1 signaling, mainly through CCL3, contributes to
tissue damage and inflammation through the enhancement
of T-cell activation, TH1 polarization, and stimulation of
macrophage function and protease secretion, and plays an
important role in the development and progression of
autoimmune diseases, such as rheumatoid arthritis and
psoriasis.25 The high levels of TNF- might be explained
by the interaction between this overexpressed chemokine
Fig. 4. Chemokine gene expression in blood samples from 29
RAS patients and 20 control individuals. The bars represent
the log2 mean fold difference  SEM of the gene expression
between the 2 groups, normalized against GAPDH mRNA
levels.and its receptors, as demonstrated in animal models, suchas an event that was dose and time dependent on CCL3
bound to CCR1, present in CD4
 lymphocytes, resulting
in additional TNF- release.31
A microarray study found hypoexpression of this
gene in RAS.16 Animal studies demonstrated that
CCR1-deficient mice also show higher TH1 immune
response and enhanced TNF- production.32,33 The
apparently conflicting results regarding CCR1 tran-
script expression could be explained by redundant and
compensatory mechanisms between CCL3 and CCR5.
TLR2 stimulation leads to gradual down-modulation of
CCR1, 2, and 5 on human blood monocytes, inhibiting
their migration following pathogen recognition, as part of
its antiinflammatory effects.24 However its function is
impaired in RAS patients,23 which might explain the high
levels of mRNA expression of CCR1 and CCR5 ob-
served.
RAS lesions are apparently a consequence of the
cytotoxic action of lymphocytes and monocytes in the
oral epithelium. The findings of the present study sug-
gest that increased expression of CCL3, CCR1, and
CCR5 may influence the immune response in RAS by
enhancement of T-cell activation and chemoattraction,
as well as by TH1 cytokine polarization.
Despite the small number of samples, the differ-
ences were strongly statistically significant between
chemokine CCL3 and chemokine receptors CCR1
and CCR5 gene expression (Figure 3) in tissue sam-
ples. However, the failure to find differences for
CCR5 and CCL3 gene expressions in blood samples
(Figure 4), even with the slightly higher number of
patients, does not exclude the possibility of a differ-
ence in expressions between RAS and control. These
results indicate that probably the mediators and re-
ceptors that showed a huge statistical significance in
a small sample represent a considerable difference
between health and disease and therefore may repre-
sent important targets for therapy and new functional
tests that could evaluate the relationship of cause and
effect for the disease.
The overexpression of the chemokine ligand and recep-
tors studied suggest participation of chemokines in RAS
manifestations, encouraging further investigations to elu-
cidate the etiopathogenesis of this oral ulcerative disease.
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